158 related articles for article (PubMed ID: 30504723)
1. Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells.
Xiao Z; Wan J; Nur AA; Dou P; Mankin H; Liu T; Ouyang Z
Cell Physiol Biochem; 2018; 51(4):1879-1893. PubMed ID: 30504723
[TBL] [Abstract][Full Text] [Related]
2. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.
Liu T; Yan Z; Liu Y; Choy E; Hornicek FJ; Mankin H; Duan Z
Cell Physiol Biochem; 2018; 46(3):1218-1230. PubMed ID: 29672299
[TBL] [Abstract][Full Text] [Related]
4. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of CD44 inhibits proliferation, migration and invasion of osteosarcoma cells accompanied by downregulation of cathepsin S.
Kong L; Ji H; Gan X; Cao S; Li Z; Jin Y
J Orthop Surg Res; 2022 Mar; 17(1):154. PubMed ID: 35264209
[TBL] [Abstract][Full Text] [Related]
6. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
[TBL] [Abstract][Full Text] [Related]
7. CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma.
Gao Y; Feng Y; Shen JK; Lin M; Choy E; Cote GM; Harmon DC; Mankin HJ; Hornicek FJ; Duan Z
Sci Rep; 2015 Jun; 5():11365. PubMed ID: 26079799
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-mediated silencing of CD44: unveiling the role of hyaluronic acid-mediated interactions in cancer drug resistance.
Xu Z
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2849-2876. PubMed ID: 37991544
[TBL] [Abstract][Full Text] [Related]
9. Silencing of CD44 gene expression in human 143-B osteosarcoma cells promotes metastasis of intratibial tumors in SCID mice.
Gvozdenovic A; Arlt MJ; Campanile C; Brennecke P; Husmann K; Born W; Muff R; Fuchs B
PLoS One; 2013; 8(4):e60329. PubMed ID: 23565227
[TBL] [Abstract][Full Text] [Related]
10. Polydatin inhibits proliferation and promotes apoptosis of doxorubicin-resistant osteosarcoma through LncRNA TUG1 mediated suppression of Akt signaling.
Hu T; Fei Z; Su H; Xie R; Chen L
Toxicol Appl Pharmacol; 2019 May; 371():55-62. PubMed ID: 30974157
[TBL] [Abstract][Full Text] [Related]
11. MAPK pathways regulation by DUSP1 in the development of osteosarcoma: Potential markers and therapeutic targets.
Lopes LJS; Tesser-Gamba F; Petrilli AS; de Seixas Alves MT; Garcia-Filho RJ; Toledo SRC
Mol Carcinog; 2017 Jun; 56(6):1630-1641. PubMed ID: 28112450
[TBL] [Abstract][Full Text] [Related]
12. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.
Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W
Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of lncRNA H19 inhibits migration and invasion of human osteosarcoma through the NF-κB pathway.
Zhao J; Ma ST
Mol Med Rep; 2018 May; 17(5):7388-7394. PubMed ID: 29568924
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-187 suppresses the proliferation migration and invasion of human osteosarcoma cells by targeting MAPK7.
Liu M; Wu L; Cai C; Liu L; Xu Y
J BUON; 2020; 25(1):472-478. PubMed ID: 32277671
[TBL] [Abstract][Full Text] [Related]
17. MiR-363 suppresses cell migration, invasion, and epithelial-mesenchymal transition of osteosarcoma by binding to NOB1.
Zhang Y; Wang F; Wang L; Zhang Q
World J Surg Oncol; 2020 May; 18(1):83. PubMed ID: 32357945
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of HCG18 Inhibits Cell Viability, Migration and Invasion in Pediatric Osteosarcoma by Targeting miR-188-5p/FOXC1 Axis.
Zhao Z; Chen J; Xia D
Mol Biotechnol; 2021 Sep; 63(9):807-817. PubMed ID: 34041718
[TBL] [Abstract][Full Text] [Related]
19. High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.
Shu H; Yuan B; Huang Y; Wang L; He B; Sun Q; Sun L
J Orthop Surg Res; 2021 Jan; 16(1):85. PubMed ID: 33509236
[TBL] [Abstract][Full Text] [Related]
20. The role of Notch ligand Jagged1 in osteosarcoma proliferation, metastasis, and recurrence.
Zhang J; Li N; Lu S; Chen Y; Shan L; Zhao X; Xu Y
J Orthop Surg Res; 2021 Mar; 16(1):226. PubMed ID: 33781318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
